Stents Drug Eluting

This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.

News

May 27, 2010 – One-year data presented this week at EuroPCR in Paris confirms sustained clinical outcomes with ...

Home May 27, 2010
Home
News

May 26, 2010 – In the constantly evolving battle for the best coronary stent, Boston Scientific said today it ...

Home May 26, 2010
Home
News

May 26, 2010 – The 12-month study results for a drug-eluting stent that uses hundreds of tiny holes, filled with ...

Home May 26, 2010
Home
News

May 25, 2010 – The highly anticipated first results of the RESOLUTE All Comers study were presented today during ...

Home May 25, 2010
Home
News

May 25, 2010 – A self-expanding, drug-eluting stent (DES) that just gained CE mark clearance in Europe is designed ...

Home May 25, 2010
Home
News

May 12, 2010 – A paclitaxel-eluting coronary stent received CE mark approval for a specific indication to treat ...

Home May 12, 2010
Home
News

May 10, 2010 – Patients treated with the Zilver PTX drug-eluting peripheral stent maintained clinical improvement ...

Home May 10, 2010
Home
News

May 7, 2010 – Findings from the SPIRIT IV trial, one of the largest randomized clinical trials comparing two drug ...

Home May 07, 2010
Home
News

May 6, 2010 – Patients who can postpone noncardiac surgery for at least six weeks after receiving a coronary ...

Home May 06, 2010
Home
News

May 6, 2010 – After entered the Japanese drug-eluting stent market earlier this year, Abbott's Xience V and ...

Home May 06, 2010
Home
News

May 3, 2010 – Excellent safety and clinical outcomes were shown in patients ages 70 and older who received a ...

Home May 03, 2010
Home
Feature | By Stephanie Labelle, senior analyst, Millennium Research Group

In recent years, many medical device companies saw the underserved lower extremity as an opportunity to enter the ...

Home May 02, 2010
Home
News

April 21, 2010 — A landmark clinical trial has begun in Europe to explore the safety and efficacy of a ...

Home April 26, 2010
Home
News

April 21, 2010 – A stent that captures endothelial progenitor cells is now combined with thin cobalt chromium ...

Home April 22, 2010
Home
News

April 21, 2010 – More than 100,000 amputations are performed each year in the United States on patients with ...

Home April 21, 2010
Home
Subscribe Now